SLC5A2 and chronic kidney disease: However, in patients under 65 years, SGLT2 inhibitors were associated with lower all-cause mortality (HR: 0.47, 95% CI: 0.23–0.99) and reduced end-stage renal disease (HR: 0.22, 95% CI: 0.06–0.82) [146].